FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895552106> ?p ?o ?g. }

• W2895552106 endingPage "147" @default.
• W2895552106 startingPage "138" @default.
• W2895552106 abstract "•Patients with peripheral arterial disease are often diagnosed with impaired renal function. •Treatment of iliac stenotic lesions using percutaneous transluminal angioplasty requires the use of nephrotoxic contrast. •Duplex-guided PTA enables endovascular treatment of iliac stenotic lesions in TASC II A and B lesions without having to rely on iodine-based or any other contrast. •This paper proves procedural success using DuPTA to be noninferior to conventional PTA in iliac stenotic TASC II A and B lesions. •These findings provide a valid alternative to perform PTA in patients with renal impairment treating iliac lesions without having to compromise for technical success. Background Percutaneous transluminal angioplasty (PTA) requires the use of nephrotoxic contrast. Patients with chronic kidney disease are more prone to develop contrast-induced nephropathy after utilization of contrast. Doppler ultrasound (duplex)-guided PTA (DuPTA) is a novel technique and has recently proven to be a successful alternative to conventional PTA in the treatment of iliac stenotic disease, without the use of contrast. In this randomized controlled trial, we evaluated whether DuPTA is as effective as conventional PTA in the treatment of iliac arterial stenotic disease. Methods From June 2013 till January 2017, 142 patients with symptomatic peripheral arterial disease (PAD), with significant (>70%) iliac stenotic lesions (both isolated and patients with multilevel disease without treatment of other lesions), were randomized to receive either conventional PTA or DuPTA of the iliac lesion, regardless of renal function. All patients received an ankle–brachial index, arterial mapping with duplex, and magnetic resonance angiography in the pre-operative work-up. Primary end point was procedural success, defined as passing the guidewire through the stenotic lesion and performing a PTA, with or without stenting. Reduction in peak systolic velocity (PSV) of ≥50% after successful PTA was required in the DuPTA group. Angiographic reduction of more than 50% was required in the interventional group. Decrease in PSV was evaluated in both groups 4 weeks post-procedure. Results Passing of the guidewire through the stenotic lesion was achieved in 96.5% of the DuPTA group and 98.8% of the PTA group (P = 0.34). Although PSV decreased significantly in both groups 4 weeks post-operative, PSV reduction ≥50% was significantly higher in the DuPTA group, respectively 78% vs. 58% in the PTA group (P < 0.01). The utilization of stents was significantly greater in the DuPTA group (52% vs. 18%, P < 0.01). After correction of potential confounders, significant difference in ≥50% PSV reduction remained; technical success did not differ significantly. Conclusions DuPTA is a feasible alternative to conventional PTA in the treatment of PAD on the iliac anatomic level. Duplex examination before removal of the guidewire is recommended to evaluate adequate decrease in PSV and identify potential recoil. Percutaneous transluminal angioplasty (PTA) requires the use of nephrotoxic contrast. Patients with chronic kidney disease are more prone to develop contrast-induced nephropathy after utilization of contrast. Doppler ultrasound (duplex)-guided PTA (DuPTA) is a novel technique and has recently proven to be a successful alternative to conventional PTA in the treatment of iliac stenotic disease, without the use of contrast. In this randomized controlled trial, we evaluated whether DuPTA is as effective as conventional PTA in the treatment of iliac arterial stenotic disease. From June 2013 till January 2017, 142 patients with symptomatic peripheral arterial disease (PAD), with significant (>70%) iliac stenotic lesions (both isolated and patients with multilevel disease without treatment of other lesions), were randomized to receive either conventional PTA or DuPTA of the iliac lesion, regardless of renal function. All patients received an ankle–brachial index, arterial mapping with duplex, and magnetic resonance angiography in the pre-operative work-up. Primary end point was procedural success, defined as passing the guidewire through the stenotic lesion and performing a PTA, with or without stenting. Reduction in peak systolic velocity (PSV) of ≥50% after successful PTA was required in the DuPTA group. Angiographic reduction of more than 50% was required in the interventional group. Decrease in PSV was evaluated in both groups 4 weeks post-procedure. Passing of the guidewire through the stenotic lesion was achieved in 96.5% of the DuPTA group and 98.8% of the PTA group (P = 0.34). Although PSV decreased significantly in both groups 4 weeks post-operative, PSV reduction ≥50% was significantly higher in the DuPTA group, respectively 78% vs. 58% in the PTA group (P < 0.01). The utilization of stents was significantly greater in the DuPTA group (52% vs. 18%, P < 0.01). After correction of potential confounders, significant difference in ≥50% PSV reduction remained; technical success did not differ significantly. DuPTA is a feasible alternative to conventional PTA in the treatment of PAD on the iliac anatomic level. Duplex examination before removal of the guidewire is recommended to evaluate adequate decrease in PSV and identify potential recoil." @default.
• W2895552106 created "2018-10-12" @default.
• W2895552106 creator A5003470466 @default.
• W2895552106 creator A5032541644 @default.
• W2895552106 creator A5045857270 @default.
• W2895552106 creator A5052264710 @default.
• W2895552106 creator A5053995038 @default.
• W2895552106 creator A5085633553 @default.
• W2895552106 date "2019-02-01" @default.
• W2895552106 modified "2023-10-16" @default.
• W2895552106 title "Duplex-guided versus Conventional Percutaneous Transluminal Angioplasty of Iliac TASC II A and B Lesion: A Randomized Controlled Trial" @default.
• W2895552106 cites W1937066294 @default.
• W2895552106 cites W1975819735 @default.
• W2895552106 cites W1978466280 @default.
• W2895552106 cites W1987477265 @default.
• W2895552106 cites W1995818276 @default.
• W2895552106 cites W1998493252 @default.
• W2895552106 cites W2000234091 @default.
• W2895552106 cites W2009882127 @default.
• W2895552106 cites W2017223163 @default.
• W2895552106 cites W2039559345 @default.
• W2895552106 cites W2042074736 @default.
• W2895552106 cites W2061514693 @default.
• W2895552106 cites W2072294693 @default.
• W2895552106 cites W2077251625 @default.
• W2895552106 cites W2105024170 @default.
• W2895552106 cites W2108863940 @default.
• W2895552106 cites W2112057860 @default.
• W2895552106 cites W2127911797 @default.
• W2895552106 cites W2144985796 @default.
• W2895552106 cites W2155965977 @default.
• W2895552106 cites W2163111941 @default.
• W2895552106 cites W2163759524 @default.
• W2895552106 cites W2165936931 @default.
• W2895552106 cites W2166286657 @default.
• W2895552106 cites W2269267463 @default.
• W2895552106 doi "https://doi.org/10.1016/j.avsg.2018.07.047" @default.
• W2895552106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30287297" @default.
• W2895552106 hasPublicationYear "2019" @default.
• W2895552106 type Work @default.
• W2895552106 sameAs 2895552106 @default.
• W2895552106 citedByCount "6" @default.
• W2895552106 countsByYear W28955521062020 @default.
• W2895552106 countsByYear W28955521062021 @default.
• W2895552106 countsByYear W28955521062022 @default.
• W2895552106 countsByYear W28955521062023 @default.
• W2895552106 crossrefType "journal-article" @default.
• W2895552106 hasAuthorship W2895552106A5003470466 @default.
• W2895552106 hasAuthorship W2895552106A5032541644 @default.
• W2895552106 hasAuthorship W2895552106A5045857270 @default.
• W2895552106 hasAuthorship W2895552106A5052264710 @default.
• W2895552106 hasAuthorship W2895552106A5053995038 @default.
• W2895552106 hasAuthorship W2895552106A5085633553 @default.
• W2895552106 hasConcept C126322002 @default.
• W2895552106 hasConcept C126838900 @default.
• W2895552106 hasConcept C141071460 @default.
• W2895552106 hasConcept C2775855180 @default.
• W2895552106 hasConcept C2777466421 @default.
• W2895552106 hasConcept C2778653478 @default.
• W2895552106 hasConcept C2780326628 @default.
• W2895552106 hasConcept C2780813298 @default.
• W2895552106 hasConcept C71924100 @default.
• W2895552106 hasConceptScore W2895552106C126322002 @default.
• W2895552106 hasConceptScore W2895552106C126838900 @default.
• W2895552106 hasConceptScore W2895552106C141071460 @default.
• W2895552106 hasConceptScore W2895552106C2775855180 @default.
• W2895552106 hasConceptScore W2895552106C2777466421 @default.
• W2895552106 hasConceptScore W2895552106C2778653478 @default.
• W2895552106 hasConceptScore W2895552106C2780326628 @default.
• W2895552106 hasConceptScore W2895552106C2780813298 @default.
• W2895552106 hasConceptScore W2895552106C71924100 @default.
• W2895552106 hasLocation W28955521061 @default.
• W2895552106 hasLocation W28955521062 @default.
• W2895552106 hasOpenAccess W2895552106 @default.
• W2895552106 hasPrimaryLocation W28955521061 @default.
• W2895552106 hasRelatedWork W1973188175 @default.
• W2895552106 hasRelatedWork W1999766840 @default.
• W2895552106 hasRelatedWork W2029381804 @default.
• W2895552106 hasRelatedWork W2033347116 @default.
• W2895552106 hasRelatedWork W2136457919 @default.
• W2895552106 hasRelatedWork W2334456746 @default.
• W2895552106 hasRelatedWork W2530060964 @default.
• W2895552106 hasRelatedWork W2977919527 @default.
• W2895552106 hasRelatedWork W3032124713 @default.
• W2895552106 hasRelatedWork W1882399356 @default.
• W2895552106 hasVolume "55" @default.
• W2895552106 isParatext "false" @default.
• W2895552106 isRetracted "false" @default.
• W2895552106 magId "2895552106" @default.
• W2895552106 workType "article" @default.